{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:15:02Z","timestamp":1787008502259,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T00:00:00Z","timestamp":1492128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Spanish Ministry of Economy and Competiveness"},{"name":"Andalusian Regional Government Council of Economy, Innovation, Science and Employment","award":["P11-CTS-7625"],"award-info":[{"award-number":["P11-CTS-7625"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Analysis"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jpha.2017.04.003","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T22:16:51Z","timestamp":1492208211000},"page":"208-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Potential of RP-UHPLC-DAD-MS for the qualitative and quantitative analysis of sofosbuvir in film coated tablets and profiling degradants"],"prefix":"10.1016","volume":"7","author":[{"given":"Mar\u00eda del Mar","family":"Contreras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"Morales-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Segura-Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpha.2017.04.003_bib1","unstructured":"World Health Organization (WHO), Hepatitis C - Fact sheet No 164,\u00a02015."},{"key":"10.1016\/j.jpha.2017.04.003_bib2","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2\u2010D\u20102'\u2010deoxy\u20102'\u2010\u03b1\u2010fluoro\u20102'\u2010\u03b2\u2010C\u2010methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2017.04.003_bib3","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpha.2017.04.003_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/cld.444","article-title":"Access to new direct-acting antiviral agents against HCV infection: a view from Spain","volume":"5","author":"Tome","year":"2015","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.jpha.2017.04.003_bib5","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.2174\/09298673113209990178","article-title":"A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir","volume":"20","author":"Gentile","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jpha.2017.04.003_bib6","first-page":"1483","article-title":"RP-HPLC method development and validation for the analyisis of telaprevir in pharmaceutical dosage forms","volume":"3","author":"Lakshmi","year":"2012","journal-title":"Int. J. Res. Pharm. Biomed. Sci."},{"key":"10.1016\/j.jpha.2017.04.003_bib7","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1128\/AAC.00281-13","article-title":"Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir","volume":"57","author":"Aouri","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpha.2017.04.003_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpba.2015.05.006","article-title":"Development of a sensitive UPLC-ESI-MS\/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: application to a bioequivalence study","volume":"114","author":"Rezk","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpha.2017.04.003_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchromb.2015.08.038","article-title":"Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC\u2013MS\/MS","volume":"1002","author":"Shi","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpha.2017.04.003_bib10","doi-asserted-by":"crossref","first-page":"98269","DOI":"10.1039\/C5RA20233G","article-title":"Quantitative performance of online SPE-LC coupled to Q-Exactive for the analysis of sofosbuvir in human plasma","volume":"5","author":"Qu","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpha.2017.04.003_bib11","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1021\/es903216p","article-title":"Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance?","volume":"44","author":"Prasse","year":"2010","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.jpha.2017.04.003_bib12","first-page":"1","article-title":"Recent trends in analytical techniques for the development of pharmaceutical drugs","volume":"S11","author":"Ravali","year":"2011","journal-title":"J. Bioanal. Biomed."},{"key":"10.1016\/j.jpha.2017.04.003_bib13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jpba.2005.06.038","article-title":"Development and validation of a high-performance liquid chromatographic method for the analysis of budesonide","volume":"40","author":"Gupta","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpha.2017.04.003_bib14","unstructured":"European Medicines Agency (EMEA), Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. CPMP\/ICH\/381\/95 - ICH Q2 (R1), EMEA,\u00a02006: 1\u201315."},{"key":"10.1016\/j.jpha.2017.04.003_bib15","doi-asserted-by":"crossref","unstructured":"Z. Li, High-throughput analysis in support of process chemistry and formulation research and development in the pharmaceutical industry, P.G. Wang (Ed.), High-Throughput Analysis in the Pharmaceutical Industry, CRC Press, Taylor & Francis Group, Boca Raton, FL, USA, 2009: 247\u2013278.","DOI":"10.1201\/9781420059540.ch9"},{"key":"10.1016\/j.jpha.2017.04.003_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jpba.2015.12.045","article-title":"Characterization of forced degradation products and in silico toxicity prediction of Sofosbuvir: a novel HCV NS5B polymerase inhibitor","volume":"120","author":"Swain","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpha.2017.04.003_bib17","unstructured":"European Medicines Agency (EMA), Assessment report. EMA\/CHMP\/688774\/2013, 2013."},{"key":"10.1016\/j.jpha.2017.04.003_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.abb.2014.06.014","article-title":"Improved high sensitivity analysis of polyphenols and their metabolites by nano-liquid chromatography-mass spectrometry","volume":"559","author":"Wilson","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jpha.2017.04.003_bib19","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/chromsci\/bmw119","article-title":"Stability-indicating method and LC\u2013MS-MS characterization of forced degradation products of sofosbuvir","volume":"54","author":"Nebsen","year":"2016","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpha.2017.04.003_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10337-016-3179-9","article-title":"RP-HPLC method for simultaneous determination of sofosbuvir and ledipasvir in tablet dosage form and its application to in vitro dissolution studies","volume":"79","author":"Zaman","year":"2016","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpha.2017.04.003_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpba.2016.01.019","article-title":"Development of a simple HPLC-UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma","volume":"121","author":"Nannetti","year":"2016","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177917300485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177917300485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:28:41Z","timestamp":1761859721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095177917300485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S2095177917300485"],"URL":"https:\/\/doi.org\/10.1016\/j.jpha.2017.04.003","relation":{},"ISSN":["2095-1779"],"issn-type":[{"value":"2095-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential of RP-UHPLC-DAD-MS for the qualitative and quantitative analysis of sofosbuvir in film coated tablets and profiling degradants","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpha.2017.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Xi'an Jiaotong University. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}